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Background: Chromosomal rearrangements in the form of deletions, insertions, inversions and translocations are
frequently observed in breast cancer genomes, and a subset of these rearrangements may play a crucial role in
tumorigenesis. To identify novel somatic chromosomal rearrangements, we determined the genome structures of
15 hormone-receptor negative breast tumors by long-insert mate pair massively parallel sequencing.
Results: We identified and validated 40 somatic structural alterations, including the recurring fusion between genes
DDX10 and SKA3 and translocations involving the EPHA5 gene. Other rearrangements were found to affect genes in
pathways involved in epigenetic regulation, mitosis and signal transduction, underscoring their potential role in
breast tumorigenesis. RNA interference-mediated suppression of five candidate genes (DDX10, SKA3, EPHA5,
CLTC and TNIK) led to inhibition of breast cancer cell growth. Moreover, downregulation of DDX10 in breast cancer
cells lead to an increased frequency of apoptotic nuclear morphology.
Conclusions: Using whole genome mate pair sequencing and RNA interference assays, we have discovered a
number of novel gene rearrangements in breast cancer genomes and identified DDX10, SKA3, EPHA5, CLTC and TNIK
as potential cancer genes with impact on the growth and proliferation of breast cancer cells.Background
The progression from normal cell, subject to stringent
growth controls, to an unregulated tumor cell is a stepwise
process of accumulating mutations and rearrangements in
the genome [1], which may disrupt, inhibit or deregulate
genes, or create novel fusion genes. However, to distin-
guish genetic alterations which confer strong advantages
to the tumor cell (drivers) from the more numerous
neutral aberrations (passengers) is a difficult task. Next-
generation sequencing has revealed somatic mutations
that may contribute to breast tumorigenesis [2-10]. Several
whole genome sequencing studies aiming at detection of
chromosomal alterations in cancer genomes have been
carried out in the past few years thanks to the advances in* Correspondence: Tobias.Sjoblom@igp.uu.se
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reproduction in any medium, provided the ormassively parallel sequencing technology [2,4,6,7,11,12].
The widely adopted method for clinical classification of
breast cancer subtypes is usually based on immunohisto-
chemical (IHC) analysis of estrogen receptor (ER), proges-
terone receptor (PR) and human epidermal receptor 2
(HER2), categorizing breast carcinomas into hormone re-
ceptor positive and HER2 negative (ER + and/or PR + and
HER2-), hormone receptor positive and HER2+ (ER + and/
or PR + and HER2+), hormone receptor negative and
HER2 positive (ER-/PR-/HER2+) and triple negative breast
cancer (TNBC, ER-/PR-/HER2-) subtypes. IHC classifica-
tion is of great value in clinical practice to predict disease
outcome as well as assign suitable targeted treatments to
patients. Hormone receptor negative breast cancers, com-
posed by HR-/HER2+ and TNBC subtypes, often correlate
with poor prognosis [13]. HER2+ cases often respond well
to treatment with trastuzumab, which is an inhibitor of
HER2-dependent signaling. However, there is no efficient
targeted therapy for TNBCs [3,5,6,12,14]. There are at
least five molecular subtypes of breast cancers defined by. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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enriched, basal-like and normal-like. HR + tumors are fre-
quently of luminal A or luminal B subtypes, while receptor
negative tumors are most frequently of HER2-enriched or
basal-like subtypes [13,15]. Recent large-scale breast can-
cer genome studies have revealed that each molecular
subtype has specific pattern of genomic alterations and
notably, tumors of HER2-enriched and basal-like subtypes
harbor many more rearrangements than the luminal A
subtype, which primarily consists of receptor positive
breast tumors [2].
In this work, we performed whole-genome sequenc-
ing on 15 hormone receptor negative breast cancers
(Additional file 1) to detect somatic gene rearrangements.
Long-insert mate pair sequencing with ~2.5 kb insert size
was chosen for increased detectability. PCR and Sanger
sequencing confirmation of selected structural variants
identified 40 novel somatic gene rearrangements and 29
genes directly affected by these alterations. We also dem-
onstrate the potential biological functions of some affected
genes by these rearrangements by RNA interference
(RNAi) in breast cell lines.
Results
Landscapes of rearrangement
Thirteen breast cancers were sequenced with Life Tech-
nologies SOLiD 3, from which a total of 119 Mb mate
pair reads were obtained, corresponding to an average
nucleotide coverage of ~0.3-fold and an average clone
coverage of 8-fold per sample. Two additional breast
tumors were sequenced with SOLiD 4 to a read depth of
3-fold nucleotide coverage and 80-fold clone coverage
on average.
Structural variations (SVs) in the form of deletions,
insertion, chromosomal translocations or inversions
were observed in 8% of all mate pairs (range 3% - 15%,
Additional file 2 and Additional file 3). The proportions
and types of SVs vary among tumors, with two tumors
having thousands of insertions (samples 120 T and 150 T,
3265 and 2466 insertions, respectively) while the other
samples have much fewer, ranging from 3 to 260. In total,
165 putative rearrangements were selected for validation
(Table 1), and 100 (61%) yielded products consistent with
the predictions from the mate pair sequencing. Of these,
60 were also found in patient-matched normal tissue
suggesting the presence of constitutional SVs, while 40
were observed only in tumor tissue and considered to be
true somatic rearrangements (Figure 1, Table 2). Somatic
SVs in individual tumors, including 8 deletions, 6 inver-
sions and 26 interchromosomal translocations, are shown
in Additional file 4. Interestingly, in one tumor sample
(sample ID 118 T), we observed at least 5 validated trans-
locations between chromosome 15 and 21, which may
imply chromothripsis [16].Genes affected by rearrangements
Twenty-nine genes were predicted to be directly affected
by the 40 validated somatic rearrangements, including
genes previously reported to be altered in cancer as well
as genes that have not yet been related to cancer (Table 2).
Using Gene Ontology (GO) [17] as a reference for poten-
tial gene functions (Additional file 5), we discovered that
these 29 affected genes are involved in multiple biological
processes including epigenetic regulation (e.g. GO:0016568
chromatin modification), cell mitosis (e.g. GO:0007067 mi-
tosis), signal transduction (e.g. GO:0007265 Ras protein
signal transduction) and others.
In order to gain insight into the functional role of some
of these genes in tumor cell growth, we performed small
interfering RNA (siRNA) knock-down analysis targeting
candidate genes CLTC (clathrin, heavy chain), EPHA5
(EPH receptor A5), SKA3 (spindle and kinetochore associ-
ated complex subunit 3), DDX10 (DEAD (Asp-Glu-Ala-
Asp) box polypeptide 10) and TNIK (TRAF2 and NCK
interacting kinase). We transfected siRNA targeting each
gene into human breast adenocarcinoma cell line MCF-7
and the mammary epithelial cell line MCF-10A. Down-
regulation of CLTC, SKA3 and DDX10 expression was
confirmed by RT-PCR in both cell lines (Figure 2A). How-
ever, we failed to evaluate the effectiveness of knock-down
for genes EPHA5 and TNIK due to poor quality of
primers. Relative cell growth (fold of siGFP-transfected
control) was 0.42 ± 0.2, 0.64 ± 0.24, 0.47 ± 0.18, 0.22 ± 0.03
and 0.37 ± 0.19 in CLTC, EPHA5, SKA3, DDX10 and
TNIK knock-down MCF-7 cell lines, respectively. Relative
cell growth in transfected MCF-10A cell lines was 0.61 ±
0.19, 0.71 ± 0.26, 0.52 ± 0.21, 0.4 ± 0.12 and 0.48 ± 0.22 for
CLTC, EPHA5, SKA3, DDX10 and TNIK respectively.
Suppression of any of these genes led to growth inhibition
in both cell lines tested (Figure 2B).
Consistent with previous studies [2,6,12], we did not
observe frequently recurrent rearrangements. The only
events that disrupted the same genes in two tumors were
translocations t(11:13)(q22.3,q12.11), which breakpoints
were located within the genes SKA3 and DDX10. SKA3
is required for spindle checkpoint silencing, the mainte-
nance of chromosome cohesion in mitosis and metaphase
to anaphase progression [18,19], whereas DDX10 encodes
a DEAD-box RNA helicase and is known to form an
NUP98-DDX10 fusion oncogene in leukemia [20]. In
addition to decreased cell growth, we observed a higher
percentage of cells with apoptotic nuclear morphology
after suppression of DDX10 expression in these MCF-7
(95 apoptotic nuclei in DDX10-suppression vs. 22 in con-
trol, per 1000 cells) and MCF-10A (66 nuclei in DDX10-
suppression vs. 34 in control, per 1000 cells) cell line. In
cells treated with siRNA targeting SKA3, apoptotic nuclei
were observed at a similar or slightly greater frequency
compared to control (Figure 2C). We also investigated the




Attempted Non-validated Constitutional Somatic Attempted Non-validated Constitutional Somatic Attempted Non-validated Constitutional Somatic
113 T 8 8 0 0 0 0 0 0 2 2 0 0
114 T 5 4 1 0 0 0 0 0 5 2 3 0
116 T 1 0 1 0 4 2 0 2 1 0 0 1
117 T 0 0 0 0 0 0 0 0 1 0 1 0
118 T 3 1 2 0 0 0 0 0 12 5 1 6
119 T 1 0 0 1 3 3 0 0 3 0 0 3
120 T 3 0 3 0 3 2 0 1 3 0 0 3
147 T 2 0 2 0 0 0 0 0 0 0 0 0
148 T 4 0 4 0 5 5 0 0 8 3 3 2
149 T 16 4 8 4 1 0 0 1 9 4 1 4
150 T 5 1 4 0 1 1 0 0 0 0 0 0
151 T 4 0 4 0 1 0 0 1 1 1 0 0
152 T 1 0 0 1 0 0 0 0 0 0 0 0
153 T 19 9 9 1 6 3 3 0 12 3 3 6
154 T 7 1 5 1 1 0 0 1 4 1 2 1
Due to the size of mate-pair inserts, insertions could not be validated by PCR. Attempted denotes the number of rearrangements attempted to validate, and Constitutional and Somatic denote the number of validated



















Figure 1 Validated somatic rearrangements in breast cancer
genomes. Outer histogram of the Circos plot shows the number of
deletions in each bin, and the inner histogram shows predicted
insertions. Connections represent PCR validated (blue lines) and
sequence validated (red lines) somatic translocations.
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vations [21,22], about 5% of MCF-7 cells and 2-3% MCF-
10A cells harbored micronuclei, while suppression of
either DDX10 or SKA3 expression did not lead to any sig-
nificant change in this frequency (Figure 2D). These find-
ings indicate that the SKA3/DDX10 alterations may have
potential roles in tumor development, and DDX10 may be
involved in pathways mediating cell apoptosis.
We also observed and validated a putative in-frame
gene fusion of PLEKHA7 and ASIC2 as a result of a trans-
location between chromosomes 11 and 17. This rearrange-
ment was constitutional rather than somatic. Nevertheless,
we cannot exclude the intriguing possibility that this fu-
sion could be driving tumorigenesis, since somatic point
mutations and rearrangements in ASIC2 have been ob-
served in previous studies [9,12,23].
Discussion
Long-insert mate pair sequencing for detecting gene
rearrangements
In this study we chose to perform long-insert (~2.5 kb)
mate pair sequencing to comprehensively identify struc-
tural alterations in receptor-negative breast cancers. Poten-
tial advantages of the approach include higher sensitivity
and higher likelihood of detecting SVs within repetitive re-
gions. Long insert lengths also reduce the need for high se-
quence coverage, especially when searching for potential
breakpoints in the chromosomes as consequences of SVs.
However, one possible drawback of long inserts couldarguably be an increased difficulty of validation, since PCR
product sizes may be prohibitively large when few reads
span a breakpoint.
In this study, the majority (65%) of validated rear-
rangements were interchromosomal, which underly the
fact that most (83%) true deletions were confirmed to be
germline variants instead of somatic events, whereas a
smaller number of translocations (35%) were present in
matched normal tissues. However, this proportion differs
from a previous investigation where interchromosomal
events only composed less than 10% of all kinds of
structural variations. Despite the limited sample size in
both studies and different classification system of rear-
rangements, the ratios of interchromosomal events to
intrachromosomal deletions and inversions in these two
studies vary to a large extent: 1.86 in our study and 0.38
in [12]. This discrepancy may be explained by the selec-
tion of rearrangements for validation in this study, since
we only attempted to confirm the SVs that occurred in
or within two insert lengths of RefSeq genes and within
two insert lengths of similar SVs in other tumors. It
might also indicate the difference in the detectability of
distinct types of rearrangement between these two stud-
ies due to approaches used (i.e. insert size of genomic
library, software for variant calling, etc.).
Potential function in cell growth and survival revealed by
siRNA knock-down analysis
Results of siRNA experiments in cell lines indicate that
the genes CLTC, EPHA5, SKA3, DDX10 and TNIK
might be functional in cell growth, and DDX10 is prob-
ably involved in cell apoptosis. However, the cell lines
MCF-7 and MCF-10A used in this analysis may be sub-
optimal since they do not represent receptor negative
breast cancers. Therefore, additional cell lines, especially
receptor negative breast cancer cell lines will need to be
studied to ultimately determine the function of these
genes in breast cancer development.
Recurrently affected genes in other cancer genome
sequencing studies
To identify potential recurrent somatic rearrangements
in breast cancer, we compared validated somatic SVs in
this study with findings from several recently published
breast cancer genome reports [2,4,6,11,12]. None of the
validated SVs were observed in any other previous studies,
demonstrating that recurrent somatic rearrangements are
very rare in breast cancers. However, some genes were
affected by somatic SVs in more than one breast cancer.
Somatic deletions in EYA1 were previously reported in
four ER + breast tumors and one TNBC [4,12], revealing
a combined prevalence of 7% (6 affected cases in a total
of 85 samples investigated). EYA1 encodes a transcrip-
tion factor where mutations have been associated with
Table 2 Genes disrupted by sequence validated somatic rearrangements discovered in breast cancers
Sample ID Chr 1 Breakpoint 1 Chr 2 Breakpoint 2 Disrupted genes
(affected regions/breakpoint locations)
Deletion 153 T 11 106618805 106622567 GUCY1A2 (exon 7)
154 T 8 72214170 72217978 EYA1 (intron 7–8)
119 T 5 134715922 134720809 H2AFY (intron 2–3)
149 T 2 12526265 12528008
149 T 2 65366656 65369602
149 T 10 22889925 22892366 PIP4K2A (intron 3–4)
149 T 15 45915722 45917969
152 T 12 2130488 2133385
Inversion 120 T 2 120331908 120335057 PCDP1 (intron 6–7)
116 T 5 129549038 129552347
149 T 10 24436405 24438757 KIAA1217 (intron 2–3)
153 T 2 172893909 175831452 METAP1D (intron 1–2), CHN1 (intron 1–2)
116 T 3 168893755 170864487 MECOM (intron 2–3), TNIK (intron 12–13)
151 T 5 137738030 137744577 KDM3B (intron 11–12)
Translocation 153 T 2 42052398 4 66411362 EPHA5 (intron 3–4)
153 T 6 104501617 X 152223450
153 T 7 54909974 19 29832131
153 T 8 57916723 19 30951050 ZNF536 (intron 2–3)
153 T 12 48517177 19 30945107 PFKM (intron 3–4), ZNF536 (intron 2–3)
153 T 19 30355201 X 153152399 LCA10 (intron 5–6)
153 T 5 174245601 10 65204015 JMJD1C (intron 1–2)
116 T 2 199768975 5 28258969
118 T 7 90081994 17 25904801 KSR1 (intron 3–4)
118 T 15 60231305 21 47148999 PCBP3 (intron 1–2)
118 T 15 60833617 21 35917066 RCAN1 (intron 1–2), RORA (intron 2–3)
118 T 15 61356378 21 41870300 DSCAM (intron 3–4), RORA (intron 1–2)
118 T 15 61375512 21 27982153 RORA (intron 1–2)
118 T 15 71750638 21 18023846 THSD4 (intron 6–7)
119 T 2 42052196 4 66411644 EPHA5 (intron 3–4)
119 T 4 4714578 17 38990874 TMEM99 (exon 3)
119 T 8 32833459 18 64563574
120 T 8 127068558 11 112588800
120 T 11 108583473 13 21735983 DDX10 (intron 10–11), SKA3 (exon 5)
120 T 13 103233303 16 77586406
148 T 2 65563071 8 80378299 SPRED2 (intron 2–3)
148 T 9 13526912 17 57745082 CLTC (intron 13–14)
149 T 1 247997045 10 27944748
149 T 3 47806974 4 151298580 LRBA (intron 48–49), SMARCC1 (intron 2–3)
149 T 5 15946143 17 67928932
149 T 11 108583658 13 21742368 DDX10 (intron 10–11), SKA3 (exon 4)
Chr 1, the lower numbered chromosome in a rearrangement; Breakpoint 1, the breakpoint position on Chr 1 determined by Sanger sequencing; Chr 2, the other
chromosome in a rearrangement; Breakpoint 2, the breakpoint position on Chr 2. Chromosome coordinates are based on human genome build HG19.
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tal abnormalities [24]. DSCAM was affected by complex
SVs including amplification, inversion, deletion and in-
terchromosomal translocation in three additional breasttumors [11,12]. DSCAM (Down syndrome cell adhesion
molecule) activates JNK and p38 MAP kinases and is im-
portant for axon guidance in the central neuron system





























































































Figure 2 Gene knockdown results in cell growth inhibition and
suppression of DDX10 leads to increased apoptosis. (A) Realtime
quantitative PCR post-transfection of esiRNAs targeting CLTC, SKA3 and
DDX10 showed efficient suppression of these three genes at the mRNA
level. Suppression of EPHA5 and TNIK was not able to be assessed
using this technique due to poor quality of primers. (B) siRNA targeting
CLTC, EPHA5, SKA3, DDX10 and TNIK transfected MCF-10A and MCF-7
cell growth in vitro relative to controls 70 h and 120 h, respectively,
after transfection is reported. Data from two independent experiments
are shown with error bars representing standard deviations. Apoptosis
(C) and micronuclei formation (D) of cell lines after transfection with
siRNA targeting DDX10 (MCF-10A, N = 2486; MCF-7, N = 2838), SKA3
(MCF-10A, N = 2823; MCF-7, N = 5035) or both siRNAs (MCF-10A,
N = 2390; MCF-7, N = 4701) was shown by numbers of cell nuclei that
exhibit apoptotic nuclear morphology and micronuclei, respectively,
per 1000 cells. siGFP transfected cells served as controls (MCF-10A,
N = 2638; MCF-7, N = 3896). Data from a representative experiment.
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required for the function of the mitotic spindle [26], were
reported in two breast tumors [4,12]. CLTC also forms
fusion genes in 25-30% of lymphomas and myofibroblastic
tumors [27]. Deletion, amplification and interchromosomal
translocation of KIAA1217 were previously discovered in
two breast cancers [11,12]. Moreover, genes EPHA5, LRBA
(LPS-responsive vesicle trafficking, beach and anchor
containing), THSD4 (thrombospondin, type I, domain
containing 4), DDX10, GUCY1A2 (guanylate cyclase 1,
soluble, alpha 2), JMJD1C (jumonji domain containing 1C),
KDM3B (lysine (K)-specific demethylase 3B), KSR1 (kinase
suppressor of Ras 1), PFKM (phosphofructokinase, muscle),
PIP4K2A (phosphatidylinositol-5-phosphate 4-kinase, type
II, alpha), RORA (RAR-related orphan receptor A),
SMARCC1 (SWI/SNF related, matrix associated, actin
dependent regulator of chromatin, subfamily c, member 1),
SPRED2 (sprouty-related, EVH1 domain containing 2),
TMEM99 (transmembrane protein 99) and TNIK have
been reported for deletions in at least one breast tumor in
previous studies [4,11,12], suggesting that the roles of these
genes in cancer merit further investigation. Interestingly,
JMJD1C was observed downregulated in breast cancers
compared to normal tissues, suggesting it as a potential
tumor suppressor gene [28]. LRBA was found upregulated
in several different cancers including ER + breast tumor,
and LRBA knockdown promotes cancer cell apoptosis [29].
Comparison of breakpoint location to array painting
study and fragile sites
We also compared the translocation breakpoints in the
present study to the total non-redundant translocation
breakpoint regions (456615397 bp) previously revealed by
array painting of three breast cancer cell lines HCC1806,
HCC1187 and ZR-75-30 [30]. Of our 2816 breakpoints
in 1408 translocations, we observe 38% within the trans-
location breakpoint regions, significantly higher than the
expected 15% (p < 1*10-194; binomial test). Out of 158
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occur at least once with putative translocations in this
study (Figure 3), altogether suggesting a correlation in
breakpoint regions of translocations in breast cancers be-
tween our study and the previous screen, which might re-
veal two possible scenarios; first, common defects in the
DNA repair mechanisms in breast cancer may led to simi-
lar patterns of chromosome breakage, or second, the
breakpoints represent driver rearrangements conferring a
selective advantage in carcinogenesis.
We also studied the overlap between the translocation
breakpoints in this study and the fragile sites of chromo-
somes (402989448 bp) previously reported by Debacker
and coworkers [31]. We observed 11% of total break-
points occur within the fragile regions, as compared to
the expected 13.4%, which suggests that there is no sig-
nificant correlation between double strand breaks and
fragile sites (binomial test). Therefore, the possibility
that the correlation between mate pair sequencing and
array painting is caused by intrinsic characteristics of
chromosomes could be ruled out.
Enrichment of consensus cancer genes in genes affected
by rearrangements
While the mechanisms and routes to breast cancer may
be complex, the accumulation of sequenced tumors willFigure 3 Overlap of translocation breakpoints and array painting. BAC
Black boxes indicate regions not overlapping with breakpoints from this study
this study, and red boxes indicate regions that contain more than one breakpeventually lead to a clearer understanding of the neces-
sary genetic rearrangements. This work focuses on 15
samples, and we identify alterations that recur not only
within our samples, but also with previous large scale stud-
ies [6,9,10,12]. Moreover, among the 29 genes disrupted
directly by SVs, 4 genes are included in the human cancer-
gene census [32]: CHN1, CLTC, DDX10 and MECOM,
suggesting an enrichment of consensus cancer genes in
our results (binomial test; p < 0.0001). However, it should
be noted that these genes may not represent all the genes
affected by the rearrangements, since only the validated
SVs were considered here and we only attempted to valid-
ate deletions, inversions and translocations that occurred
in or near RefSeq genes.
The distribution of SVs varies markedly, reflecting the
unique genetic composition of each tumor. However, the
most striking difference is in the number of insertions,
where two samples (120 T and 150 T) have thousands of
insertions, in contrast to much lower numbers in other
samples (Additional file 6). This does not seem to be the
consequence of differences in sequence coverage, since
the two most deeply sequenced samples harbor only 67
insertions in total. BRCA1 and BRCA2 mutational ana-
lyses detect no germline mutations in the two patients
with extremely large numbers of insertions, indicating
that this feature is not caused by deficiency in DNAregions studied by Howarth et al. are shown as boxes on the ideogram.
, blue boxes indicate regions in which one breakpoint was observed in
oint. The gray shadows represent chromosome bands.
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tations. The bulk of the insertions in samples 120 T and
150 T tend to be shorter with an average insertion
length of roughly 600 bp, compared to about 1000 bp in
other samples (Additional file 7 and Additional file 8),
which may suggest a different mutagenesis mechanism
in these two samples.
Conclusions
In this study we identify gene rearrangements in receptor
negative breast cancer genomes using long-insert whole-
genome mate pair sequencing. Somatic rearrangements
disrupting genes composed by both known cancer genes
and genes not previously correlated with cancer have been
validated. These genes include epigenetic regulators, genes
involved in mitosis and multiple signaling pathways and
other genes whose functions are largely unknown. Con-
sistent with previous studies [12], we did not observe fre-
quently recurrent rearrangements, which verify the fact
that breast cancer is a highly heterogeneous disease that a
large number of low-frequency rearrangements may syn-
ergistically contribute to its development.
Methods
Sample handling, DNA library construction and mate pair
sequencing
The study was approved by the Regional Ethical Review
Board of Uppsala (2007/116). Fifteen breast cancer spec-
imens with paired DNA from adjacent normal breast
tissue derived from a part of the breast resectate that
was devoid of macroscopic tumor were analyzed. Tumor
cellularity was more than 50% in all the tumor samples
while the normal tissues were confirmed not containing
any tumor cells by microscopic inspection by a patholo-
gist. Two out of the 15 patients had previous malignan-
cies in the ovary or cervix, respectively. All cancer
samples showed negative staining of hormone receptors
ER and PR, whereas three of the 15 samples exhibited
overexpression of HER2, determined by IHC (Additional
file 1). Genomic DNA was extracted from SDS-Proteinase
K digested fresh frozen tissues by phenol-chloroform.
Qualification and quantification of DNA was carried out
by NanoDrop (Thermo Scientific) and real-time PCR, re-
spectively. BRCA1 and BRCA2 mutation analysis was
performed by PCR followed by Sanger sequencing of
all protein coding regions of the two genes in normal
DNA samples.
Thirty μg of DNA from each sample were used to con-
struct SOLiD3 or SOLiD4 mate-pair libraries according
to the manufacturer’s instructions. Briefly, the DNA was
sheared into fragments of about 2,500 bp by HydroShear
(Genomic Solutions) and end-repaired using End Polishing
Enzyme 1 and 2. Cap adaptors (50-pACAGCAG-30, 50-CA
TGTCGTCp-30) are ligated to both ends of the fragments.Next, the adapter ligated DNA sample was separated on a
0.8% agarose gel and DNA fragments of about 2,500 bp in
length were recovered and purified. The sizes and concen-
trations of adapter ligated DNA strands were quantified
using a Bioanalyzer kit (DNA 7500, Agilent). The samples
were circularized using a biotinylated internal adaptor,
nick-translated with E.coli DNA polymerase 1 and digested
with T7 exonuclease and S1 nuclease. Digested DNA was
end-repaired using End Polishing Enzyme 1 and 2 and
bound to streptavidin beads. P1 (50-CCACTACGCCTCC
GCTTTCCTCTCTATGGGCAGTCGGTGAT-30, 50-ATC
ACCGACTGCCCATAGAGAGGAAAGCGGAGGCGTA
GTGGTT-30) and P2 adaptors (50-AGAGAATGAGG
AACCCGGGGCAGTT-30, 50-CTGCCCCGGGTTCCT
CATTCTCT-30) were ligated to the fragments. The
libraries were further nick-translated followed by PCR-
based amplification and released from the beads. PCR
products were separated on a 4% agarose gel and the 250–
350 bp library bands were recovered, purified, and verified
using a Bioanalyzer kit (Agilent, DNA 1000). Throughout
the library preparation procedure, DNA was purified and
concentrated with QIAquick columns (QIAGEN) after
each enzymatic reaction and PCR. Emulsion PCR was per-
formed according to the manufacturer's manual (SOLiD3
System Templated Bead Preparation Guide, Life Tech-
nologies) before SOLiD sequencing. Subsequently, 50 base
pairs from each end were collected on the Life Technolo-
gies SOLiD3 or SOLiD4 instrument. Genotype data have
been deposited at the European Genome-phenome Arch-
ive (EGA, http://www.ebi.ac.uk/ega/), which is hosted by
the European Bioinformatics Institute, under accession
number EGAS00001000438.
Sequence alignment and rearrangement detection
The resulting reads were mapped to the human genome
(HG18) using Corona Lite (Applied Biosystems). All reads
with ambiguous paired mappings and all redundant pairs
were removed. The insert lengths between paired ends
were compared to the corresponding distances between
their alignments against the reference genome in order to
detect indels, and inversions were detected by disparate
strand orientations of paired alignments. Similarly, frag-
ments whose ends mapped against different chromosomes
may suggest inter-chromosomal rearrangements such as
translocations or transpositions of DNA between chromo-
somes. Fragments were greedily clustered if they report
the same type of rearrangement at the same chromosomal
position, resulting in predicted structural variations (SVs).
To filter out spurious rearrangements, first, the SVs which
were also observed in control samples from two healthy
individuals (previously reported in [33]) were removed.
Second, we removed all events situated within two insert
lengths from telomeric or centromeric regions, or known
gaps in the reference genome. Third, known variations
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moved. This process removed on average 89% of putative
somatic SVs (Additional file 2 and Additional file 9).
Finally, for insertions and translocations, we analyzed
the positioning of anchors versus the reference genome.
Essentially, we assumed that a genuine translocation or
transposition is characterized by a correlation in the posi-
tions of mate-paired anchors; as the upstream anchor
position increases, so should the downstream anchor pos-
ition. In the case of an inversion, we expect an inverse re-
lationship between the upstream and downstream anchor.
In terms of correlation between upstream position and
downstream position, we expect a strong and significant
positive correlation between up- and downstream anchors
in case of a same-orientation translocation while a strong
and significant negative correlation between anchors is
expected in case of an inverted translocation. We there-
fore calculated the correlation coefficient between anchor
positions on each chromosome in order to further exclude
false positives caused by repetitive sequences from true
positive inter-chromosomal rearrangements. Transloca-
tions with significant positive or negative correlation coef-
ficients were considered more likely to be true positives. A
detailed study of the statistical properties of translocations
has been carried out (Hooper et al., submitted). All gen-
ome coordinates of rearrangements were converted to
the latest human genome version HG19 for the readers’
convenience by LiftOver (http://genome.ucsc.edu/cgi-bin/
hgLiftOver).
Rearrangement validation by PCR and capillary
sequencing
Rearrangements were selected for validation if they fulfill
all of the three criteria: (1) occured in or within two in-
sert lengths of RefSeq genes, (2) were supported by at
least four reads, and (3) occured within two insert
lengths of similar rearrangements in other tumor sam-
ples. Exception applied to the validation of transloca-
tions in the two deeply sequenced samples (113 T and
114 T), in which the cutoff of supporting reads were set
to 40 instead of 4 mate pairs and only those with signifi-
cant anchor correlation were attempted for confirmation
(Hooper et al., submitted). We furthermore consider the
impact and interest of rearrangements to increase with
read support, since it may reflect both a higher degree of
accuracy and proportion of the total tumor population.
Additionally, primer design is more accurate due to lar-
ger target sizes.
To validate selected putative rearrangements, we de-
signed forward and reverse PCR primers within a 200-bp
range as close as possible to the breakpoints using Pri-
mer3 [35] and verified against the human reference ge-
nome (hg18) using Bowtie [36]. Primers were discarded if
they had multiple matches to the reference or predicted toyield too large PCR products. This approach minimizes
the expected PCR product size and increases the chance
of detection. Primers were based on the DNA on either
side of a breakpoint, and were not allowed to be within
the reads they were designed to validate. For each chosen
deletion, inversion and translocation, up to 5 different pri-
mer pairs were evaluated in PCR to enhance detectability.
Insertions could not be validated directly by PCR due to
the large product sizes. PCR for each selected candidate
rearrangement was carried out on both tumor DNA and
patient-matched normal DNA in parallel to determine
whether the rearrangements were somatic. The PCR prod-
ucts of somatic rearrangements were further purified and
analyzed by capillary sequencing in order to determine
the exact breakpoints and those that obtain sequences
covering the rearrangement breakpoints were considered
as validated somatic rearrangements.
RNA interference in normal and malignant breast cells
MCF-7 cells were cultured in McCoys 5A (Gibco)
supplemented with 10% FBS (Gibco) and penicillin-
streptomycin (100 μg/ml each, Gibco). MCF-10A cells
were cultured in phenol red-free DMEM-F12 media
(Gibco) supplemented with 5% heat-inactivated horse
serum (Gibco), hydrocortisone (0.5 μg/ml, Sigma-Aldrich),
insulin (10 μg/ml, Sigma-Aldrich), epidermal growth factor
(0.02 ng/ml, PeproTech), cholera toxin (0.1 μg/ml, Sigma-
Aldrich) and penicillin-streptomycin (100 μg/ml each,
Gibco). Mission endoribonuclease-prepared small interfer-
ing RNA (esiRNA) targeting CLTC, DDX10, EPHA5, SKA3
and TNIK were obtained from Sigma-Aldrich. MCF-7 and
MCF-10A cells were transfected using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA). GFP specific siRNA
(AACUUCAGGGUCAGCUUGC) was used as a control.
In order to measure the efficiency of depletion, total RNA
was extracted using QIAamp RNA Blood Mini kit (Qiagen)
48 h after esiRNA transfection and the cDNA was gener-
ated from 1 μg total RNA with RevertAid H Minus First
Strand cDNA Synthesis kit (Fermentas) according to the
manufacturer’s instruction. Real-time quantitative PCR was
done using an Applied Biosystems StepOne qPCR instru-
ment (PCR conditions and primers are available upon re-
quest). Data analysis was performed using the software
provided by Applied Biosystems Inc with β-actin as a refer-
ence gene. For cell growth assays, cells (100 000 cells/well
for MCF-7 and 50 000 cells/well for MCF-10A) seeded in
12-well tissue culture plates were transfected 24 h later with
esiRNA. MCF-7 and MCF-10A cell growth was determined
in the Incucyte system (Essen Instruments, Ann Arbor, MI,
USA) according to the manufacturer’s instruction 120 h
and 70 h after transfection, respectively.
For investigation of micronuclei and apoptosis forma-
tion, cells (30 000 cells/well for MCF-7 and 18 000 cells/
well for MCF-10A) were seeded in LabTekII 8 well
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http://www.biomedcentral.com/1471-2164/14/165chamber slides (Nunc). The cells were allowed to attach
overnight and then transfected with esiRNA targeting
DDX10 and/or SKA3. After 24 h growth in the incu-
bator, slides were fixed in 3.7% formaldehyde (Sigma-
Aldrich) for 15 min. Cell nuclei were stained with
Hoechst 33342 (1:10 000 in 1xPBS) for 40 min. Cells were
imaged with a Zeiss AxioImager M2 fluorescence micro-
scope. The total number of cells, the number of micro-
nuclei and the number of apoptotic cell nuclei were
determined manually from the images using the Cell Coun-
ter Plugin for ImageJ 1.45 s.Additional files
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